PMID- 13679663
OWN - NLM
STAT- MEDLINE
DCOM- 20031023
LR  - 20220410
IS  - 1424-8832 (Print)
IS  - 1424-8832 (Linking)
VI  - 32
IP  - 5-6
DP  - 2002 Sep-Dec
TI  - Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach.
PG  - 308-11
AB  - Retinal vein occlusion (RVO) is a relatively common disease, often associated 
      with the presence of diseases related to internal medicine. It is well known that 
      RVO is associated with common systemic vascular disorders such as hypertension, 
      arteriosclerosis and diabetes. Several studies using hospital-based controls have 
      shown an increased risk of RVO in patients with arteriopathy, or high levels of 
      plasma glucose and arterial blood pressure. Patients are categorized into six 
      types of RVO based on the site of occlusion and on the type of consequent 
      vascular damage. Central retinal vein occlusion (CRVO) is the most 
      frequently-occurring and clinically relevant type of RVO. In addition to the 
      well-known classical risk factors, new haemostasis-related ones have been 
      investigated in patients affected by CRVO. While data concerning a number of 
      parameters remain contradictory, high levels of type 1 plasminogen activator 
      inhibitor (PAI-1) and hyperhomocysteinemia appear to play a significant role in 
      the pathogenesis of this disease. Although based on a limited number of studies, 
      this new knowledge could eventually provide important indications regarding 
      prognosis and therapeutic strategies. There is no established treatment for CRVO. 
      Treatment consists primarily of managing any identified underlying systemic 
      disease. The increasing role of hypercoagulability in patients with CRVO supports 
      the use of antithrombotic drugs in the treatment of this disease. Vitamin 
      treatment to correct hyperhomocysteinemia should also be taken into 
      consideration. However, the approach to CRVO treatment with antithrombotic drugs 
      is not evidence-based yet. There is urgent need of intervention trials to 
      evaluate the role of these drugs in CRVO patients.
FAU - Prisco, Domenico
AU  - Prisco D
AD  - Department of Medical And Surgical Critical Area, Section of Clinica Medica 
      Generale e Cliniche Specialistiche, University of Florence, Florence, Italy. 
      priscod@ao-careggi.toscana.it
FAU - Marcucci, Rossella
AU  - Marcucci R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Pathophysiol Haemost Thromb
JT  - Pathophysiology of haemostasis and thrombosis
JID - 101142710
RN  - 0 (Fibrinolytic Agents)
SB  - IM
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Humans
MH  - Retinal Vein Occlusion/*drug therapy/*epidemiology/etiology
MH  - Risk Factors
RF  - 6
EDAT- 2003/09/19 05:00
MHDA- 2003/10/24 05:00
CRDT- 2003/09/19 05:00
PHST- 2003/09/19 05:00 [pubmed]
PHST- 2003/10/24 05:00 [medline]
PHST- 2003/09/19 05:00 [entrez]
AID - 73587 [pii]
AID - 10.1159/000073587 [doi]
PST - ppublish
SO  - Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):308-11. doi: 10.1159/000073587.